|
ZSGB Biotech
rabbit anti-human mesothelin antibody ep140 Figure S7 . " width="250" height="auto" />Rabbit Anti Human Mesothelin Antibody Ep140, supplied by ZSGB Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rabbit+anti+mesothelin/pmc11722131-8-0-7?v=ZSGB+Biotech Average 90 stars, based on 1 article reviews
rabbit anti-human mesothelin antibody ep140 - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Absolute Biotech Inc
rabbit anti mesothelin Figure S7 . " width="250" height="auto" />Rabbit Anti Mesothelin, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rabbit+anti+mesothelin/pmc09197998-829-0-3?v=Absolute+Biotech+Inc Average 86 stars, based on 1 article reviews
rabbit anti mesothelin - by Bioz Stars,
2026-07
86/100 stars
|
Buy from Supplier |
|
Rabbit anti-Mesothelin(C-terminus) Antibody
|
Buy from Supplier |
|
Rabbit anti-Mesothelin(C-terminus) [+Biotin] Antibody, 50 µg
|
Buy from Supplier |
|
Mesothelin antibody [N1C2], 1 mg/ml (100 µl)
|
Buy from Supplier |
Image Search Results
Figure S7 . " width="100%" height="100%">
Journal: Cell Reports Medicine
Article Title: Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state
doi: 10.1016/j.xcrm.2024.101869
Figure Lengend Snippet: Miltefosine enhances CAR-T cell efficacy against solid tumors in vivo (A) Experimental timeline of CDX model and the fold change of tumor volume in CAR-T cell-treated CDX mouse model in the presence or absence of miltefosine administration (PBS group, n = 3; other groups, n = 5). (B) Tumor weight of each group at the end of experiment (PBS group, n = 3; other groups, n = 5). (C) The percentages of mesothelin- and hCD3-positive area in tumor tissues (PBS group, n = 2; other groups, n = 5). Scale bar: 200 μm. (D) The fold change of tumor volume in CDX mouse model treated with CAR-T cells derived from another donor, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (E) The proportion of hCD3 + T cells in the peripheral blood of CDX mouse model ( n = 4). (F) The fold change of tumor volume in CAR-T cell-treated PDX mouse model, in the presence or absence of miltefosine or anti-PD-1 antibody treatment ( n = 4). (G) The proportion of hCD3 + T cells in the peripheral blood of PDX mouse model ( n = 4). Unpaired t test was used in statistical analysis. (H) Experimental timeline of the OT-1-treated melanoma isograft tumor model. (I) The fold change in tumor volume in the OT-1-treated melanoma isograft tumor model in the presence or absence of miltefosine administration ( n = 7). Unpaired t test was used in statistical analysis. NS, not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. All error bars denote SEM. See also
Article Snippet:
Techniques: In Vivo, Derivative Assay
Journal: Cell Reports Medicine
Article Title: Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state
doi: 10.1016/j.xcrm.2024.101869
Figure Lengend Snippet:
Article Snippet:
Techniques: Functional Assay, Flow Cytometry, Control, Recombinant, Lysis, Activation Assay, Transfection, Luciferase, Viability Assay, SYBR Green Assay, RNA Sequencing Assay, Construct, Plasmid Preparation, Software